EBV Positive Gastric Carcinomas and Their Clinicopathological Characteristics
DOI:
https://doi.org/10.3889/oamjms.2018.409Keywords:
EBV, gastric carcinoma, immunohistochemistry, clinicopathological characteristicsAbstract
BACKGROUND: The understanding of the etiopathogenesis of gastric carcinoma (GC) can be a base for development of new therapeutic methods to reduce mortality and to increase survival in patients with GC. The percentage of Epstein - Barr virus (EBV) positive gastric carcinomas is uncertain, and the etiologic importance of EBV in the pathogenesis of GC has still not been elucidated.
AIM: This study aimed to determine the percentage of EBV associated GC as well as to determine their clinicopathological characteristics.
MATERIAL AND METHODS: The study included 80 patients with GC who were analysed for ethnicity, local growth of a tumour (T status), the presence of nodal metastases (N), the presence of distant metastases (M), stage of the disease and degree of carcinoma differentiation. For detection of EBV, immunostainings were performed on tumour tissue and the peripheral non-tumour gastric mucosa.
RESULTS: Positive immunostaining with an antibody against EBV was found in 19 (23.75%) of the 80 patients with gastric carcinomas. EBV immunostainings were significantly different in patients with or without metastasis and between patients of Macedonian and Albanian ethnicity (p < 0.0001, p < 0.009, respectively). EBV immunoexpression was significantly associated with the presence of distant metastases and with patients of Albanian ethnicity.
CONCLUSION: Association of EBV immunostainings with distant metastasis in patients with GC suggests the influence of EBV infection on the progression of gastric carcinoma. Due to scarce and doubtful literature data on EBV associated GC, further studies are necessary to determine the role of EBV regarding aetiology, treatment and prognosis in patients with EBV associated gastric carcinoma.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin. 2005; 55:74–108. https://doi.org/10.3322/canjclin.55.2.74 PMid:15761078
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61:69 90. https://doi.org/10.3322/caac.20107 PMid:21296855
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versussurgery alone for resectable gastroesophageal cancer. New Eng J Med. 2006; 355(1):11–22. https://doi.org/10.1056/NEJMoa055531 PMid:16822992
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgerycompared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med. 2001; 345(10):725–730. https://doi.org/10.1056/NEJMoa010187 PMid:11547741
Murphy G, Pfeiffer R,Constanza Camargo CM, Rabkin C.Meta-analysis Shows That Prevalence of Epstein–Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic Location. Ggastroenterology. 2009; 137:824–833. https://doi.org/10.1053/j.gastro.2009.05.001 PMid:19445939 PMCid:PMC3513767
Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. Exp Clin Cancer Res. 2009; 28:14. https://doi.org/10.1186/1756-9966-28-14 PMid:19192297 PMCid:PMC2642773
Kim Y, Shin A, Gwack J, Ko KP, Kim CS, Park SK, Hong YC, Kang D, Yoo KY. Epstein-Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study. Br J Cancer. 2009; 101(3):526-9. https://doi.org/10.1038/sj.bjc.6605146 PMid:19550421 PMCid:PMC2720236
Tokunaga M, Land CE. Epstein-Barr virus involvement in gastric cancer: biomarker for lymph node metastasis. Cancer Epidemiol Biomarkers. 1998; 7:449–450.
Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol. 2000; 53:255–61. https://doi.org/10.1136/mp.53.5.255 PMid:11091849 PMCid:PMC1186978
Fukayama M, Hayashi Y, Iwasaki Y, et al. Epstein-Barr virus associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest. 1994; 71:73–81. PMid:8041121
Burgess DE, Woodman CB, Flavell KJ, et al. Low prevalence of Epstein-Barr virus in incident gastric adenocarcinomas from the United Kingdom. Br J Cancer. 2002; 86:702–4. https://doi.org/10.1038/sj.bjc.6600107 PMid:11875729 PMCid:PMC2375309
Wang HH, Wu MS, Shun CT, et al. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein-Barr virus infection. Hepatogastroenterol. 1999; 46:1214–9.
Herrera-Goepfert R, Akiba S, Koriyama C, Ding S, Reyes E, Itoh T, Minakami Y, Eizuru Y. Epstein-Barr virus-associated gastric carcinoma: Evidence of age-dependence among a Mexican population. World J Gastroenterol. 2005; 11(39):6096-103. https://doi.org/10.3748/wjg.v11.i39.6096 PMid:16273633 PMCid:PMC4436624
Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and Molecular Characteristics of Epstein-Barr Virus-associated Gastric Carcinoma: A Meta-analysis. J Gastroenterol Hepatol. 2009; 24(3):354-65. https://doi.org/10.1111/j.1440-1746.2009.05775.x PMid:19335785
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Ljubomir Ognjenovikj, Aleksandar Shumkovski, Stojan Gjoshev, Goce Volchevski, Gjorgji Trajkovski, Zoran Karadzov, Darko Dzambaz, Dragan Hadzi-Manchev, Todor Hadzi-Manchev, Gordana Petrushevska, Vesna Janevska, Vlado Janevski, Nikola Brzanov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
